Trial Profile
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2016
Price :
$35
*
At a glance
- Drugs Gemcitabine elaidate (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- 30 Jan 2016 New trial record